Among the many medical and therapeutic applications of psychedelics being explored in labs and boardrooms today, Alzheimer’s disease has maintained a relatively low profile. But that may be changing, thanks in part to a review article published last summer in Frontiers in Synaptic Neuroscience.1 “We have been stunned by the popularity of our article on the Frontiers platform…


Previous articleMindMed Announces Successful Completion of Pre-IND Meeting with the FDA for Project Lucy
Next articlePatent Combining Psychedelics with Cannabinoids Allowed by USPTO